Immunotherapeutic application of induced pluripotent stem cell technology: Rejuvenated BCMA-specific CD8+T cells for multiple myeloma.

被引：0
|
作者：
Bae, Jooeun [1 ]
Kitayama, Shuichi [1 ]
Herbert, Zach [1 ]
Daheron, Laurence [1 ]
Munshi, Nikhil [1 ]
Kaneko, Shin [1 ]
Ritz, Jerome [1 ]
Anderson, Kenneth [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6347
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myeloma
    Bae, Jooeun
    Kitayama, Shuichi
    Herbert, Zach
    Daheron, Laurence
    Kurata, Keiji
    Keskin, Derin B.
    Livak, Kenneth
    Li, Shuqiang
    Tarannum, Mubin
    Romee, Rizwan
    Samur, Mehmet
    Munshi, Nikhil C.
    Kaneko, Shin
    Ritz, Jerome
    Anderson, Kenneth C.
    BLOOD, 2024, 143 (10) : 895 - 911
  • [2] Rejuvenated BCMA-specific CD8ab+memory T cells to treat multiple myeloma using induced pluripotent stem cell technology
    Bae, Jooeun
    Kitayama, Shuichi
    Herbert, Zach
    Daheron, Laurence
    Kurata, Keiji
    Munshi, Nikhil
    Kaneko, Shin
    Anderson, Kenneth
    ANNALS OF ONCOLOGY, 2023, 34 : S1389 - S1390
  • [3] Rejuvenated BCMA-Specific CD8 + Cytotoxic T Lymphocytes Derived from Antigen-Specific Induced Pluripotent Stem Cells : Immunotherapeutic Application in Multiple Myeloma
    Bae, Jooeun
    Kitayama, Shuichi
    Daheron, Laurence
    Herbert, Zach
    Munshi, Nikhil C.
    Kaneko, Shin
    Ritz, Jerome
    Anderson, Kenneth C.
    BLOOD, 2021, 138
  • [4] Rejuvenated BCMA-specific CD8+Cytotoxic T lymphocytes derived from induced pluripotent stem cells for treatment of Multiple Myeloma
    Bae, Jooeun
    Kitayama, Shuichi
    Daheron, Laurence
    Herbert, Zach
    Munshi, Nikhil C.
    Ritz, Jerome
    Kaneko, Shin
    Anderson, Kenneth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S84 - S84
  • [5] Selective Targeting of Multiple Myeloma By Bcma-Specific Central Memory CD8+ cytotoxic T Lymphocytes: A Potential Immunotherapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders
    Bae, Jooeun
    Hideshima, Teru
    Munshi, Nikhil
    Anderson, Kenneth C.
    BLOOD, 2018, 132
  • [6] DEVELOPMENT OF B CELL MATURATION ANTIGEN (BCMA)-SPECIFIC CD8+ CYTOTOXIC T LYMPHOCYTES USING INDUCED PLURIPOTENT STEM CELL TECHNOLOGY FOR MULTIPLE MYELOMA
    Bae, Jooeun
    Kitayama, Shuichi
    Herbert, Zach
    Daheron, Laurence
    Munshi, Nikhil
    Ritz, Jerome
    Kaneko, Shin
    Anderson, Kenneth
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1265 - A1265
  • [7] Development of B-cell maturation antigen (BCMA)-specific CD8+ cytotoxic T lymphocytes using induced pluripotent stem cell technology for multiple myeloma
    Bae, Jooeun
    Kitayama, Shuichi
    Herbert, Zach
    Daheron, Laurence
    Munshi, Nikhil C.
    Kaneko, Shin
    Ritz, Jerome
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] BCMA-SPECIFIC TAC RECEPTOR-ENGINEERED T CELLS FOR MULTIPLE MYELOMA
    Bezverbnaya, K.
    Lau, V.
    Aarts, C.
    Denisova, G.
    Afsahi, A.
    Cummings, D.
    Helsen, C. W.
    Bramson, J.
    CYTOTHERAPY, 2018, 20 (05) : S9 - S9
  • [9] Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
    Fan, Frank
    Zhao, Wanhong
    Liu, Jie
    He, Aili
    Chen, Yinxia
    Cao, Xingmei
    Yang, Nan
    Wang, Baiyan
    Zhang, Pengyu
    Zhang, Yilin
    Wang, Fangxia
    Lei, Bo
    Gu, Liufang
    Wang, Xugeng
    Zhuang, Qiuchuan
    Zhang, Wanggang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [10] Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
    Fan, Frank
    Zhao, Wanhong
    Liu, Jie
    He, Aili
    Chen, Yinxia
    Cao, Xingmei
    Yang, Nan
    Wang, Baiyan
    Zhang, Pengyu
    Zhang, Yilin
    Wang, Fangxia
    Lei, Bo
    Gu, Liufang
    Wang, Xugeng
    Zhuang, Qiuchuan
    Zhang, Wanggang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345